Journal Club: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial

Description

Listen to a new Journal Club with lead author Dr. Angeles Alvarez Secord and moderator Dr. Robert Coleman as they discuss details on the recently published article The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial. Click here to read the article

Presented by:

A person in a black suitDescription automatically generated

Angeles Alvarez Secord, MD, MHSc
Professor of Obstetrics and Gynecology
Duke University School of Medicine
USA

Moderated by:

A person in a suit and tieDescription automatically generated

Robert Coleman, MD, FACOG, FACS
Chief Medical Officer
Vaniam Group
USA

Supported in part by

Summary

Availability:

On-Demand

Cost:

FREE

Create Account

Recommended

Personalized Management of Advanced or Recurrent Endometrial Cancers: Navigating pMMR, dMMR Subtypes, or Molecular Classifications

FREE

Redefining Platinum Sensitivity : Additional Treatment Considerations in a Changing Paradigm

FREE

From Data to Practice: Integrating Key Phase III Results into Ovarian Cancer Management

FREE

IGCS 2024 Endometrial Cancer Master Session

FREE

IGCS 2024 Cervical Master Sessions: Moving Forwards

FREE

Patient reported outcomes exploring quality of life in PROC and novel therapeutics: mirvetuximab in recurrent ovarian cancer

FREE

Journal Club: Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

FREE

IGCS 2024 Ovarian Master Sessions: The Era of Targeted Therapies

FREE

Journal Club - Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB–IVA

FREE